Abstract The development of investigational medicinal products from pre-clinical package to product launch is a process that may be beset by pitfalls and expensive failures. The focus of this review is to provide an overview of how the conventional design of early phase oncology clinical trials has been modified with the advent of molecular profiling into treatment paradigms. We identify classical and alternative trial endpoints in an era of molecularly targeted agents and immunotherapy, and consider how personalised medicine has impacted on clinical trial design with reference to basket, umbrella and multi-arm expansion cohorts. Finally, we assess the impact of agile, adaptive and 'intelligent' trial design for patients, clinicians and trial centres, and how these challenges may be overcome to accelerate the approval of novel drugs for patient benefit.
Overview of Conventional Early Phase Clinical Trial Design
Drug development and clinical trial design from preclinical package to post-marketing surveillance classically proceeds in defined phases (Table 1) . Early phase clinical trials are typically defined as Phase 0 to Phase 2a (nonrandomised) clinical trials. The primary objective of early phase clinical trial design is the assessment of safety and tolerability [1] , identification of the recommended Phase 2 dose (RP2D) and to obtain preliminary data on the efficacy of a novel investigational medicinal product (IMP) or combination in human subjects. Integral to early phase clinical trial design is the careful review of the pre-clinical drug development package [2] [3] [4] . Phase 0 studies are exploratory studies of limited duration (typically \7 days), which are performed to investigate proof of mechanism of the novel IMP in human subjects or pharmacokinetic/pharmacodynamic biomarkers of IMP activity. A micro-dosing strategy is utilised where less than 1/100 of the minimal pharmacological effective dose of the IMP is administered based on extrapolation from pre-clinical animal data. Phase 0 trials have no therapeutic value to the trial participant and may be performed in healthy volunteers and provide an early feasibility assessment of IMP activity and biodistribution. In addition, Phase 0 clinical trials may allow lead optimisation of candidate drugs for interaction with a particular therapeutic target. As the risk of toxicity is significantly reduced by limited drug exposure, the regulatory requirements for conduct of Phase 0 trials are less stringent than for a Phase 1 or 2 design [5] . As such, Phase 0 trials are a relatively inexpensive way to achieve human exposure data, determine biological activity of the IMP and reduce development of IMPs that fail to engage adequately with the therapeutic target.
In Phase 1 clinical trial design, the primary objective is the identification of the RP2D of the IMP [6] . To achieve dose-finding in Phase 1 clinical trials, a 'safe' starting dose is first calculated using preclinical data and published guidance to estimate a maximum safe starting dose [2] . In the absence of toxicity, dose escalation may be rapid to ensure that the fewest participants are exposed to a suboptimal dose. Whereas with emerging toxicity, dose escalation should be more circumspect to reduce risk of patient harm. Toxicity in phase 1 clinical trials may be complex and idiosyncratic and so a meticulous approach to patient assessment and data collection is always required.
There are two broad approaches to Phase 1 clinical trial design: traditional (rule-based) or adaptive (model-based). In traditional Phase 1 clinical trial design, no assumption is made regarding the relationship between dose and toxicity. IMP toxicity is assessed using standardized guidelines such as the Common Terminology Criteria for Adverse Events (CTCAE) [7] . The dose escalation strategy is predetermined by the trial protocol, according to safety, tolerability and pharmacokinetics (PK) observed usually during the first cycle at the previous dose level. The escalation modality may vary from a classic 3 ? 3 design, rolling 6, Fibonacci, accelerated dose titration or Bayesian model [8] . Traditional Phase 1 design is statistically powered to accept a dose-limiting toxicity (DLT) incidence of \33%. Once the RP2D has been determined, a small expansion cohort is often included to interrogate pharmacodynamic (PD) effects, the optimal biological dose (OBD) and proof of concept (POC). A drawback of this conventional approach is that it is slow, expensive and does not integrate cumulative toxicity data into dose finding. Dose finding may be imprecise where biological efficacy and toxicity of an IMP are not closely coupled. Furthermore, a significant proportion of trial participants may be exposed to a suboptimal dose of the IMP [9] .
Adaptive (model-based) Phase 1 clinical trial design may be preferable for the conduct of more complex combination IMP clinical trials, or where efficacy and toxicity are measured simultaneously to facilitate rapid clinical development of an IMP [10] [11] [12] [13] . In this context, the dosetoxicity curve is statistically predefined before trial recruitment begins, based on preclinical data and prior assumptions of the IMP. As the trial proceeds, the dose escalation model is adapted based on cumulative toxicity data, which may be weighed against relative exposure to the IMP of the trial participants. For some drugs with robust preclinical PK data, pharmacokinetically guided dose escalation trial designs can be used in which escalations are based on the drug exposures observed [14] . By real-time incorporation of (cumulative) toxicity, PK and PD data, an 'intelligent' model-based design can achieve optimal dose finding and an early read-out for biological endpoints. Adaptive trial designs are therefore preferable to assess chronic toxicity, which is particularly relevant for some molecularly targeted agents (MTAs) where symptoms such as fatigue may occur beyond the first cycle of treatment and can be significant for tolerance. Adaptive designs have been demonstrated to be more efficient than '3 ? 3' designed trials with the ability to explore more dose levels and to produce higher maximum tolerated dose (MTD) to starting dose ratios [15] compared with traditional Phase 1 trial designs. However, adaptive trials require continued statistical support, which may be a barrier for their use in some trial centres. Despite the advantages of adaptive designs, a lack of investigator familiarity has sometimes lead to lower uptake than traditional approaches in investigatorled and commercial clinical trials [16] .
The purpose of Phase 2a studies is to assess the safety, tolerability and biological effectiveness of an IMP in a larger non-randomised patient population. The objective is to assess whether the IMP warrants further testing and development in a larger, and more costly, randomised Phase 2b/3 setting, acting as a go/no-go decision point. A read-out of adverse events (AEs) in a larger patient population can also be measured. With the increasing use of large dose expansion cohorts in Phase 1 trials, there is now a notable overlap between Phase 1 and 2a clinical trials.
Clinical Endpoints in Early Phase Trials
The classical endpoint in Phase 1 trials is the RP2D, which is calculated based on the MTD. MTD is a toxicity-based endpoint measured in the first evaluable cycle of treatment (21-to 28-day period), often in an unselected 'all-comers' trial population. DLT is generally defined as grade 3 or 4 IMP-related toxicity but may include cumulative grade 2 toxicity lasting more than 7 days, despite supportive medications. MTD is particularly relevant to cytotoxic chemotherapies, which have a linear dose-response relationship. Alternative tolerability endpoints may include time to onset of AEs/DLTs, or the proportion of patients requiring a dose reduction or interruption.
The OBD is the dose of an IMP associated with the most favourable change in a selected PD, PK or functional imaging biomarkers. OBD is a biological endpoint for the purposes of early phase clinical trials. The use of OBD may allow a more tolerable, but biologically active, dose to be selected. However, the use of OBD requires strong preclinical data supporting the mechanism of action of the drug and the change it produces on the target, which is not always available. Often, both PD and PK biomarkers have insufficient preclinical testing to accurately confirm their relationship with changes in tumour growth rates [17] . Paired biopsies are the gold standard method of confirming the degree of target inhibition, but they are invasive and associated with risks to patients [18] . Surrogate tissues, such as peripheral blood mononuclear cells and hair follicles, may be used but may not accurately reflect the effect seen in the tumour cells which harbour the genetic aberration being targeted. Functional imaging techniques and liquid biomarkers, such as circulating tumour cells and circulating free DNA, potentially provide novel mechanisms of assessing PD effects [19, 20] . The ease of repeated sampling allows serial monitoring of patients' tumours to predict and assess response to treatments and the emergence of resistant clones [21, 22] . A circulating free DNA (cfDNA) companion diagnostic received FDA approval to determine epidermal growth factor receptor (EGFR) mutation status in patients with NSCLC for decisions about EGFR tyrosine kinase inhibitor treatment, highlighting the potential utility of liquid biopsies as predictive biomarkers [23] .
In recent years, there has been a decrease in the proportion of trials using MTD to determine the RP2D, particularly in the case of MTAs, with just 58% using MTD as their primary endpoint [24] . MTAs preferentially target an aberrant pathway within cancer cells, with relative sparing of the normal tissues. Therefore, traditional toxicities associated with DLT definitions and MTD may not be attained in preclinical animal studies of MTAs or within a 21-to 28-day evaluable period of a Phase 1 study. In a recent review of patients on Phase 1 trials of MTAs, 18.6% of subjects experienced their first toxicity of grade 3 or higher after cycle 1 [25] , thus rendering traditional MTD assessment suboptimal. Furthermore, escalating doses of MTAs may not be associated with increased response, where response is determined by engagement or occupancy of the biological target. For immunotherapies (ITs), biological endpoints, toxicity and efficacy read-out may not be determined for many months and are not intrinsically dose related. Consequently, toxicity assessment and dose finding for MTAs and ITs, both in preclinical development and Phase 1 trials, is challenging.
Efficacy is increasingly assessed in early phase drug development, particularly in large dose expansion cohorts of Phase 1 trials to aid in decision making for novel IMP development. Regulatory agencies have utilised response data such as progression free survival (PFS) from Phase 1 trials in their assessment and registration of novel agents. To this end, the FDA created a ''breakthrough therapy'' designation, which can lead to accelerated drug approval pathways. This has resulted in increased focus on efficacy as an endpoint in Phase 1 trials, driving larger expansion cohorts. One example of this is the accelerated FDA approval of pembrolizumab, an anti-PD-1 monoclonal antibody, for use in melanoma [26] .
As many patients on Phase 1 trials are heavily pretreated, such response data may underestimate the activity of an IMP. Other efficacy endpoints that could be considered include the clinical benefit rate (CBR), which incorporates the rates of stable disease, partial and complete responses. The ratio of the PFS for the novel agent under evaluation compared to the PFS on the prior line of therapy for patients may also be used to evaluate an IMP [27] . In the future, clinical trial protocols will need to be statistically powered to meet meaningful response objectives while remaining flexible so they can adapt to emerging data of novel IMPs.
Adapting Early Phase Clinical Trial Design for Precision Medicine
The drive towards personalised medicine has impacted on all aspects of drug development including early phase clinical trials. Personalised or precision medicine involves tailoring treatment for an individual patient based on their specific characteristics and those of their tumour, to maximize response whilst minimizing toxicity. The increased focus on utilising personalised medicine within oncology has influenced early phase trial design, increasing enrichment for patient groups of interest, rather than traditional ''all comer'' Phase 1 trials. This is, in part, driven by the increased availability of next generation sequencing techniques allowing the selection of patients for clinical trials based on specific genomic aberrations. On a molecular level, relative response to novel IMPs is fundamentally determined by cancer heterogeneity, which may be intertumoral, intra-tumoral and inter-cellular. Specifically, there may be variability between different trial participants with the same histological subtype of disease, regional heterogeneity between different sites of disease within the same trial participant, or between a primary tumour and a metastasis within the same trial participant. Agile clinical trial designs, which prospectively select trial participants based on the molecular profile of their tumour and the mechanism of the IMP, have already led to 'smaller and smarter' trial design and acceleration of drug development. Improved technological advances mean that it is possible to identify and drug molecular targets, and monitor effect through PD assays, with the caveat that the sensitivity of cancer to a targeted agent may be modified by cancer type, e.g. c-kit in GIST, EGFR in lung cancer. Where there is robust preclinical data regarding the mechanism of the IMP and a predictive biomarker of disease response, patient enrichment in both the escalation and expansion phases of a trial should be considered. Genomic-based trial designs such as umbrella and basket studies allow the relationships between molecular aberrations, clinical characteristics, histology and the response to an IMP to be explored (Table 2) .
Basket trials are a histologically agnostic trial design which recruit patients whose tumours contain a specific genomic aberration of interest ( Fig. 1a ; Table 2 ). Vemurafenib, a BRAF inhibitor, was trialled in patients whose tumours contained V600E alterations, irrelevant of histology (though excluding the licensed indication of melanoma) [28] . High response rates were seen amongst patients with non-small cell lung cancer (NSCLC) but also in rare tumours such as Erdheim-Chester disease and Langerhans' cell histiocytosis, highlighting the benefit of the basket trial design for patients with rare tumours. An ongoing large basket trial study is the NCI Molecular Analysis or Treatment Choice (MATCH) study (NCT02465060) in which patients with any tumour histology are allocated to one of 24 arms based on the presence of actionable mutations identified within a new biopsy [29] .
Umbrella trials, in contrast to basket trials, recruit patients with one histological diagnosis, but then allocate patients to specific arms within the trial based on the presence of specific molecular alterations in their tumours ( Fig. 1b; Table 2 ). This design allows multiple MTAs to be tested for a specific histological indication within one trial. The Lung MAP trial (Lung Cancer Master Protocol trial; NCT02154490) is an example of an umbrella trial in which patients with squamous NSCLC are matched to arms testing different MTAs based on molecular aberrations within the tumours [30] . The ISPY-2 trial (the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Biomarker Analysis 2) (NCT01042379) is a novel randomised umbrella trial design which adapts to emerging data using Bayesian methods [31, 32] . In ISPY-2 the efficacy of novel agents and their associated biomarkers is assessed in combination with neoadjuvant treatment, for the treatment of primary breast cancer. New experimental arms can be added to the trial based on emerging data and successful arms can be taken on to large Phase 3 studies for further evaluation.
Essential to the success of genomic-based studies is the use of robust and reliable biomarkers to identify appropriate patients. Successful cohorts can then be expanded to generate further data whilst underperforming cohorts can be closed allowing the trial to adapt to emerging evidence.
Strong preclinical data regarding the mechanism of action of the IMP under investigation is required to ensure the biomarker selects for the correct group of patients. The infrastructure to rapidly perform genomic screening also must be in place within the trial organisation and the trial centres. As the molecular aberrations of interest may be rare, these trials are often multicentre, requiring collaboration between multiple sites and reducing the experience of any single investigator with these drugs.
Another approach to personalised oncology is the use of Algorithm Testing Personalised Medicine Trials. These are molecular screening studies that allow randomised or nonrandomised allocation of patients to matched IMP based on their molecular profile, often using molecularly targeted agents outside their licensed indication [33, 34] . In these circumstances, it is unusual for the clinical trial to be powered sufficiently to robustly assess efficacy of the IMP and instead such early phase clinical trials act as a test of the efficacy of the molecular screening programme and molecular tumour board. One example is the WINTHER trial (NCT01856296), a modified ''N of 1'' trial where subjects recruited act as their own control. Two hundred patients will be recruited to the trial and their PFS on an agent selected utilising profiling techniques will be compared to the PFS on their prior line of treatment [35] . The Targeted Agent and Profiling Utilization Registry (TAPUR) Study (NCT02693535) is another example, which aims to explore the use of molecularly targeted agents outside of their licensed indication. Patients enrolled in the study will be allocated to one of 15 arms based on the presence of actionable mutations within their tumour, with each arm exploring the use of an FDA-approved targeted agent outside its licenced indication. Project GENIE (Project Genomics Evidence Neoplasia Information Exchange) is attempting to capitalise on the large amount of sequencing being performed on oncology patients [36] . Data from clinical grade sequencing performed at eight international cancer centres have been collated with some associated clinical data, with the hope of driving forward clinical and translational research. To date, data from the sequencing of 19,000 patients with 59 types of cancer have been released. Project GENIE highlights the collaboration needed to utilise the increasing volumes of data generated from cancer research, which could aid rational novel trial design. However, experience from other personalised oncology trials has shown that successful matching of trial participant to IMP and meaningful clinical benefit is not automatically attainable [34] . Also, relying on efficacy results from uncontrolled clinical trials may bias improvements in outcomes that might reflect the prognostic nature of the target, rather than a true treatment effect [37] .
Within oncology trial design, there has been an increasing trend to perform large multi-arm Phase 1b dose expansions on completion of dose escalation studies to gain further information about efficacy and toxicity of the IMP used at the RP2D ( Fig. 1c; Table 2 ). This technique allows Fig. 1 Design of basket, umbrella and multi-arm dose expansion early phase trials. a Schematic of design of basket trials. In a basket trial, patients with multiple tumour histology but with one specific mutation or genomic aberration are treated with a molecularly targeted agent. b Schematic design of umbrella trials. In an umbrella trial, patients with one single tumour histology are recruited and assigned to arms based on the presence of specific mutations or genomic aberrations. Patients with one specific mutation or aberration may all receive the same drug or may be randomised to one of two treatments. c Schematic design of multi-arm dose expansion. In a multi-arm dose, expansion, patients from selected indications of interest are treated at the RP2D. RP2D recommended phase 2 dose, IMP investigational medicinal product, PDL1 programmed deathligand 1 study assessing pembrolizumab. After determination of MTD there were multiple dose expansion arms in both patients with melanoma and NSCLC. Pembrolizumab received accelerated FDA approval on the basis of efficacy data from the Phase 1b dose expansion in 135 patients with melanoma 3 years after clinical development began [26] . Large dose expansion cohorts were also carried out in the Phase 1 trial of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, to carry out POC assessments with mandatory biopsies to assess T790M status. After two subsequent single-arm Phase 2 trials, one of which was an extension of the initial Phase 1 trial, osimertinib received accelerated FDA approval [39, 40] . The development of both pembrolizumab and osimertinib highlight how drug development is evolving to try to streamline the process rather than stick to the rigid formula of a Phase 1, 2 and 3 studies. To be effective, dose escalations need clearly stated aims and objectives and justification for the proposed patient numbers [41] . Modular trial designs, which seek to add multiple combination arms without a specific trial objective or rationale within the original research, are unlikely to be viewed favourably by regulatory agencies. Protocols need to be created that justify the planned design whilst having an element of flexibility to accommodate emerging data from the dose escalation. The increasing size of Phase 1 studies, particularly driven by expansion cohorts, necessitates changes in how Phase 1 units are run to cope with the greater capacity needed.
Drug Development Strategies in Response to Resistance
Genetic heterogeneity within cancer has been a focus of research for many years. Low genetic frequency events may be selected during systemic anti-cancer therapy, becoming dominant at cancer recurrence. Therefore, if tumour bulk is large and mitotic cell turnover is large, the capacity for resistance is also large. At present, the true frequency of polyclonal drug resistance is likely underestimated, due to drug development being confined either to the interrogation of a limited number of resistance mechanisms, or else a limited number of samples. With modern research capabilities, evolving treatment resistance can now be tracked with increasing sophistication, for example, using serial liquid biopsy [20, 42] or patient derived xenografts (PDX) an 'avatar' of the patient [43] . From these and other models, it is clear that cancer therapy may alter cancer biology and is a selective pressure for survival and genetic/molecular adaption of cancers. Genetic changes within a tumour may be 'truncal', i.e. present in every cancer cell and potentially predictive of treatment sensitivity and resistance, e.g. ROS1 amplification in lung cancer predicting sensitivity to crizotinib [44, 45] , or 'branch', i.e. only present in a subpopulation of cancer cells, e.g. acquired T790 resistance mutation developed in sub-clones of heterogeneous NSCLCs, during rociletinib therapy [46, 47] .
Non-genetic mechanisms of resistance are frequently not assessed, for example, the generation of BRAF splice variants or gene overexpression. With conventional sequential systemic therapy strategies for most tumour types, multiple resistance mechanisms may be present within the same patient or indeed within the same metastatic deposit. A further layer of complexity is added where the molecular profile of an archival tumour specimen is compared to circulating tumour DNA or the molecular profile of circulating tumour cells [48, 49] . Computational network-based algorithms can be used to examine gene regulation, signalling pathways, the effects of the immune system and the impact of the tumour microenvironment to identify potential therapeutic targets in the treatment of resistant disease [50, 51] . High throughput system-based approaches can also be used to identify novel combinations for drug testing [52, 53] .
Response rates to single-agent therapies remain low and resistance, both intrinsic and acquired, represents a significant challenge. Combination treatment, in which both agents are rationally chosen for their possible synergy, represent an area of increased interest within oncology, with the potential to overcome resistance and by so doing, improve outcomes. However, the challenges of singleagent phase 1 trials are amplified when combining two or more therapies. It could be argued that adaptive trial designs, in contrast to rule-based designs, are a better suited method for combination studies given the ability of some methods to utilise both toxicity and efficacy data, long-term toxicity data and consider all available data. However, utilisation of adaptive methods to date has been limited, with just 4% of combination studies assessed in one review using adaptive as opposed to rule-based designs [54] . Combination studies require robust preclinical data as their basis with evidence of synergy or additivity of the combination therapy as opposed to single-agent use of drugs, which is sometimes lacking [55] . One of the challenges for combination treatments is the potential for overlapping toxicities, which can be difficult to identify from preclinical models [56] . For example, despite the clear scientific rationale for combining drugs targeting the MEK and PI3K pathways, clinical trials of combinations of these agents have been hampered by significant issues with AEs including diarrhoea and rashes [57] . The potential for PK interactions adds another layer of complexity to Phase 1 combination studies, for example, an unexpected interaction between pazopanib and lapatinib resulted in suboptimal doses of lapatinib, reinforcing the importance of accurate PK data [58] . The benefits and challenges of combination trials are exemplified by the combination of ipilimumab and nivolumab in melanoma in which PFS was 11.5 months for the combination therapy as opposed to 2.9 months for ipilimumab alone and 6.9 months for nivolumab alone [59] . However, the rate of grade 3 and 4 toxicities was 55% for the combination in contrast to 27.3% for ipilimumab alone and 16.3% for nivolumab alone. The real tantalising feature of this trial was the possibility of a cohort of long-term survivors, highlighting the real potential of combination trials.
A key challenge for the physician in targeting treatment resistance is knowing which mutation to treat, and when to treat. Targeting truncal mutations may be the optimal therapeutic strategy, but this excludes patients with subclonal actionable mutations who may also derive benefit from targeted therapy. Where truncal mutations are drugged, there may be a negative impact on accelerating the formation of other sub-clonal 'branch' mutations. One therapeutic response to these challenges is to combine agents up-front to hit as many clones as possible, or the rational sequencing of targeted agents to treat one clone after another.
Learning from History
Over the last 15 years, there has been a seismic expansion in the clinical development of MTAs and ITs for the treatment of multiple cancers. A review of 71 anticancer drugs (most of which were MTAs) approved by the US FDA in the last decade, showed that the median gain in overall survival was 2.1 months [60] . For 23 of these drugs, FDA approval was gained on the basis of an improvement in PFS (median 2.5 months) rather than overall survival (OS). Consequentially, there is increasing recognition of a mismatch between the cost of new drugs and benefit to patients, and that clinical trial design should actively consider clinically meaningful endpoints in OS and PFS, which may vary dependent on tumour type and current available therapies. Thus, the degree of benefit from an IMP must be weighed against the risks of adverse outcome to the patient. A higher toxicity profile may be acceptable if there is a large survival gain compared with that which is acceptable when there is marginal survival advantage. Furthermore, quality-of-life outcome measures should also be considered in the assessment of novel IMPs.
One example of a modest improvement in median overall survival is with bevacizumab in metastatic colorectal cancer. In 2013, bevacizumab was granted FDA approval for use where progression had occurred within 3 months of first-line bevacizumab-combination (5FU-irinotecan or 5FU-oxaliplatin) chemotherapy. In the bevacizumab-chemotherapy arm of the trial, an improvement in median overall survival from 9.8 to 11.2 months was observed, and for PFS, the difference was 1.7 months. However, these endpoints were measured from the time the patient enrolled into the trial, and when the data were reanalysed from the start of the first-line treatment, there was no statistical significance between the bevacizumab-combination chemotherapy versus the combination chemotherapy alone cohort [61] . In view of this, a number of ASCO disease specific working groups (Breast, Lung, Colorectal and Pancreatic Cancer) have recently defined PFS and OS outcomes measures, which should be the aspirational benchmark for future clinical trials [62] .
The identification of specific driver oncogenic mutations and the ability to develop drugs that target such mutations is integral to precision therapy. Constitutive activation of the BRAF gene, as a result of somatic mutations, was first described in 2002 [63] . Sorafenib is a multi-kinase inhibitor with activity against several targets including the BRAF gene, which became available for clinical investigation simultaneously with preclinical data supporting a role for the BRAF mutation as an oncogenic driver. However, the clinical results from Phase 2 and Phase 3 trials in patients with melanoma were disappointing [64] [65] [66] [67] and subsequent comparison of pre-and posttreatment biopsies revealed that sorafenib was an ineffective inhibitor of the MAPK pathway. Lessons learnt from this and other similar examples are that mechanistic validation of target inhibition pre-clinically in cultured cells and xenografts does not necessarily translate to similar activity in humans. Furthermore, promising therapeutic targets should not be disregarded based on the failure of a reputed inhibitor.
The example of the BRAF gene also illustrates how incomplete understanding of the biological relevance of a molecular target, with reference to tumour-specific indications, can hinder drug development. In metastatic melanoma, the development of more potent and selective BRAF inhibitors vemurafenib and dabrafenib, with demonstrable inhibition of ERK phosphorylation in paired tumour biopsies, led to dramatic improvements in PFS and OS compared with chemotherapy in patients whose tumours harboured the BRAF V600E mutation. It was therefore logical to assume that vemurafenib and dabrafenib would have similar efficacy in patients with BRAF V600E mutation bearing metastatic colorectal cancer, but the same clinical benefit was not observed [68, 69] . This was explained by compensatory 'escape' pathways in colorectal cancer leading to incomplete MAPK blockade.
In an era of costly novel IMPs active in only a subpopulation of tumour types, there is an increasing drive to define biomarkers predictive of response in the 'right' (most treatment-sensitive) patient population. A good example of this dilemma is IT, where a minority of patients develop durable responses with prolonged remissions. Unlike chemotherapy, responses to IT may occur later and are not defined by the number of prior lines of therapy. Whilst historically novel IMPs have evaluated drugs by tissue type, anti-CTLA4 and anti-PD-1 or anti-PD-L1 ITs have efficacy in multiple cancer types. In metastatic renal cancer for example, several clinical trials have assessed the predictive value of programmed death ligand-1 (PDL-1) expression as a predictive biomarker of response to nivolumab (PD-1 inhibitor) and atezolizumab (PDL-1 inhibitor), with conflicting results between trials and between primary and metastatic sites of disease [70, 71] . In refractory colorectal cancer, the overall response to pembrolizumab is low in unselected 'all-comers' cohorts. However, where the mismatch repair deficiency is pre-selected, the response rate rises to 40% [72] . Therefore, targeted therapies may not always have a single predictive biomarker and in the case of IT several biomarkers may be predictive dependent on the tissue of origin, including PDL-1 expression. The response to IT may also be modulated by the immunogenic microenvironment, type I immunity, mutational load and disease burden, amongst other factors.
Future Impact on Early Phase Drug Development
The move away from small rule-based all-comer dose escalation trials to adaptive trial design, patient enrichment and larger Phase 1 trials is producing changes for patients, clinicians and trial centres. Phase 1 trials are becoming larger with greater numbers of patients competitively recruited to large dose expansion studies. Trial centres need to have the capacity to manage larger volumes of patients on multiple studies. As many studies are carried out at multiple centres, the experience of any one clinician with the agent under investigation will be reduced. Frequent teleconferences are required to enable dissemination of data about AEs and DLTs between the sites. The complexity of running large multi-arm studies across several sites has led to the increased use of clinical research organisations to manage trials. The increased use of genetic screening to determine eligibility for trials necessitates trial centres to have processes in place to rapidly access archival tissue or carry out fresh biopsies in a timely fashion. Trial centres also need to consider how they will support patients who are ineligible once the screening has been completed, particularly when screening for rare abnormalities, and may need to have a diverse trial portfolio to manage these outcomes. If molecular profiling is required to determine eligibility for trials, the organisers of trials need to ensure the tests can be turned around rapidly on receipt of a patient's tumour tissue. This is not only to minimise patients' anxiety whilst awaiting the results, but also to minimise loss of patients to the study, either through patients clinically deteriorating and no longer being fit enough for trials, or patients opting for alternative trials. Targeting rare molecular abnormalities may necessitate establishing large pre-screening programmes at multiple sites to identify sufficient patients for a clinical trial, and so associated costs for the screening programme and carrying out the set up and training for the trial at many sites. For example, in the initial Phase 1 trial of crizotinib, approximately 1500 patients were screened to identify 82 patients with NSCLC whose tumours contained ALK gene rearrangements [73] . In contrast, for patients with more common genetic events, there can be multiple studies competing to recruit the same pool of patients. The prevalence of the molecular aberration of interest in the target population of patients will therefore influence the design of the trial.
Conclusions
In oncology, compared with other areas of drug development, approval rates for novel drugs remain low and drug development times prolonged [74, 75] . This highlights the need for clinical trials to ensure streamlined drug development which delivers efficacious drugs to patient groups with unmet need. Novel trials using adaptive designs, novel endpoints and enrichment of target patient groups are therefore required to meet these needs. However, irrelevant of the trial design the fundamental pillars of Phase 1 remain the same and need to be optimised. Robust preclinical data is the bedrock to support drug development into the clinical phase. In the past, there have been doubts about the reliability and reproducibility of preclinical data; going forward, preclinical data need to be held to the same rigorous standards as clinical data [76] . Clinical trials need to be well designed to ensure they generate the data to meet the trials aims and to ensure that the questions being asked from clinical trials are relevant to patients' care. Early phase trials should include comprehensive PK and PD analyses for POC confirmation, and potentially to improve the efficiency and cost effectiveness of drug development and to avoid costly errors in later phases of trials [77, 78] . In oncology, there remains significant unmet need, and drug development must evolve to meet this challenge by utilising novel and adaptive clinical trial designs.
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